

## PDX Data Sheet for COG-N-625x

**Disease:** Neuroblastoma  
**Phase of Therapy:** Post-Chemotherapy (Progressive Disease)  
**Treatment:** ANBL00B1 (Chemotherapy, Surgery), ACCL1031 (Caphosol or saline-placebo), ACCL0934 (levofloxacin or not), AEPI07N1 (Observational / Genetic study)  
**Disease Stage:** 4  
**Gender:** Male  
**Age at diagnosis:** 59.8 months  
**Race:** NA  
**Age at sample collection:** 100.4 months  
**Source of culture:** Tumor (adrenal) surgery April 2016  
**Primary tumor site:** Adrenal gland, NOS Suprarenal gland Adrenal  
**Date Established:** June 2016

**MYCN Patient:** NA  
**MYCN PDX:** Relative copy number – 3 copies  
**TH mRNA:** Expressed  
**p53 functionality:** NA  
**Telomere Mechanism:** TERT negative, C-circle+  
**ALK:** Wild Type

**PDX RNAseq:** Available upon request  
**PDX WES:** Available upon request  
**Strain of Mice:** NSG or Athymic NuNu (recommended)  
**Injection Type:** Subcutaneous  
**Growth Properties:** 20e6 cells minimum, ~6 months to 1500mm<sup>3</sup>; mice can become obese  
 Please see Protocols section at  
<https://www.cccells.org/protocols.php>

**Human vs. Mouse:** This PDX model has been tested and confirmed over multiple passages to be above 95% human cells.

**STR Profile:** May be obtained at <https://strdb.cccells.org/>

**Notes:** NA

**h-IMPACT Profile I IDEXX:** PCR evaluation of EBV, HAdV, Hantaan, HCMV, Hepatitis A, Hepatitis B, Hepatitis C, HHV 6, HHV8, HIV1, HIV2, HSV 1, HSV 2, HTLV 1, HTLV2, LCMV, Mycoplasma sp., Seoul, Sin Nombre, VZV were all negative.

---

## PDX Data Sheet for COG-N-625x

---

**Cell Line Name:** COG-N-625x

**References:**



---

## PDX Data Sheet for COG-N-625x

---

**PDX Name:** COG-N-625x

**H&E slides**